Understanding the risks of different tobacco products for vulnerable groups
Communicating about Nicotine and Differential Risks of Tobacco Products in Priority Populations
This study is looking at the best ways to explain the risks of different tobacco products, especially very low nicotine cigarettes, to help people, especially those with mental health issues or from low-income backgrounds, understand them better and make healthier choices about smoking.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Georgia State University NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project ID | NIH-11019708 on NIH RePORTER |
What this research studies
This research investigates how to effectively communicate the risks associated with various tobacco products, particularly focusing on very low nicotine cigarettes (VLNCs). It aims to develop targeted messaging that addresses common misconceptions about VLNCs and their potential benefits for priority populations, such as individuals with mental health conditions and those from low socioeconomic backgrounds. By combining insights from previous clinical trials and real-world product use, the study seeks to enhance the effectiveness of tobacco reduction policies. Participants may engage in discussions and activities that help shape these messages and assess their impact on smoking behavior.
Who could benefit from this research
Good fit: Ideal candidates for this research include smokers from economically deprived backgrounds or those with mental health conditions.
Not a fit: Patients who do not smoke or are not part of priority populations may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved public health outcomes by reducing tobacco use and its associated harms in vulnerable populations.
How similar studies have performed: Previous research has shown that very low nicotine cigarettes can reduce addiction and smoking rates, indicating a promising approach to tobacco harm reduction.
Where this research is happening
Atlanta, United States
- Georgia State University — Atlanta, United States (Active)
Researchers
- Principal investigator: Popova, Lyudmila — Georgia State University
- Study coordinator: Popova, Lyudmila
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.